Corporate Announcements - Jiangnan Water received a stake increase from Lian'an Life, reaching 5.03% of total shares [3] - Yingboer plans to transfer 100% equity of Zhuhai Dingyuan for 239 million yuan to optimize asset structure [4] - Chengbang Co. experienced a five-day stock price surge, diverging from its fundamentals, with a warning about market risks [5] - Weimais intends to invest 190 million yuan in its subsidiary for a new electric drive assembly project, expected to take 12 months [6] - Fosun Pharma's subsidiary received EU GMP certification for its production facilities, marking a significant compliance achievement [7] Performance Highlights - Foton Motor reported a 150.96% year-on-year increase in new energy vehicle sales for the first half of the year, totaling 50,142 units [9] - Meinuohua expects a net profit increase of 142.84% to 174.52% for the first half of 2025, driven by revenue growth and improved gross margins [10] - Madi Technology anticipates a net profit of 25 to 27 million yuan for the first half of 2025, marking a turnaround from a loss of 76.33 million yuan in the previous year [11] Major Contracts - Dash Intelligent signed a contract for an intelligent project worth 11.88 million yuan, representing 0.37% of its 2024 revenue [13] - Jinyi Industrial won a bid for a 335 million yuan materials procurement project for the Nanjing-Huaian intercity railway [14] Share Buybacks - Kweichow Moutai repurchased 72,000 shares in June, totaling 1.02 billion yuan, with a cumulative buyback of 3.38 million shares amounting to 5.202 billion yuan [16] - Feiwo Technology plans to repurchase shares worth 25 to 50 million yuan for equity incentives, with a maximum price of 43.44 yuan per share [17] Shareholding Changes - Renfu Pharmaceutical's shareholder,招商生科, plans to increase its stake by 1% to 2% within six months, with a price cap of 25.53 yuan per share [19] Financing Activities - CITIC Securities received approval to issue up to 20 billion yuan in perpetual subordinated bonds [21]

Group 1 - CITIC Construction Investment has received approval from the China Securities Regulatory Commission to issue perpetual subordinated bonds with a total face value of no more than 20 billion yuan [1] - Bluefocus Technology has received a loan commitment of up to 900 million yuan from CITIC Bank for stock repurchase [1] - Huaren Pharmaceutical's subsidiary has received approval for the listing of Bumetanide raw materials, which are used to treat severe heart failure and hypertension emergencies [3] Group 2 - Betta Pharmaceuticals has received approval for the listing of Enasidenib capsules in Macau, aimed at treating ALK-positive locally advanced or metastatic non-small cell lung cancer [4] - Juewei Food plans to use 110 million yuan of idle fundraising for cash management, with an expected annual yield of 1.00%-1.89% [6] - China Huadian has successfully completed the issuance of 1 billion yuan medium-term notes with a coupon rate of 1.95% [9] Group 3 - Fosun Pharma's subsidiary has received a GMP certificate from the Belgian Federal Agency for Medicines and Health Products for the production facilities of two monoclonal antibodies [11] - China Nuclear Engineering has signed a civil engineering contract for the Taishan Nuclear Power Units 3 and 4 [13] - Kanglongda has faced administrative regulatory measures from the Zhejiang Securities Regulatory Bureau due to the failure of performance commitment parties to fulfill compensation obligations [15] Group 4 - Gaoling Information has received three invention patent certificates in the second quarter, covering various technological fields [16] - Weimais plans to use 190 million yuan of excess fundraising to increase capital in its subsidiary for building a new energy vehicle powertrain production base [17] - Huazhong Technology has received a project designation notice from a leading eVTOL manufacturer for the development and supply of an intelligent cockpit multimedia display system [19] Group 5 - Madi Technology expects a net profit of 25 million to 27 million yuan for the first half of 2025, marking a turnaround from a loss in the previous year [19] - Dazhong Mining's subsidiary has obtained a mining license for the Zhouyoufang Iron Mine, increasing production capacity to 6.5 million tons per year [20] - Zhongguancun's subsidiary has had its application for the listing of Arolol hydrochloride tablets accepted by the National Medical Products Administration [21] Group 6 - Tianhong Co. has signed a property management contract worth 15 million yuan with a local company [22] - Dong'an Power has secured nine new market designation agreements in the second quarter, with a projected total sales volume of 1.5 million units [24] - Zhujiang Co. has appointed Zhao Kun as the new deputy general manager [25] Group 7 - Jinyi Industrial has won a bid for a project worth 335 million yuan from the China Railway Shanghai Bureau Group [26] - Kangchen Pharmaceutical has received a clinical trial notification for its innovative drug KC1086, aimed at treating advanced solid tumors [27] - Changhua Group has received a project designation notice from a new energy vehicle company, with an expected total sales amount of 970 million yuan [29] Group 8 - Lingxiao Pump Industry plans to use 60 million yuan of idle funds to purchase financial products [31] - Mould Technology has received a project designation for exterior parts from a well-known North American electric vehicle company, with an expected total sales of 1.236 billion yuan [34] - Fulongma has pre-bid for five sanitation service projects in June, with a total contract amount of 181 million yuan [35] Group 9 - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange [36] - *ST Yuancheng is under investigation by the CSRC for suspected false financial disclosures [37] - Beilu Pharmaceutical's subsidiary has received approval for the listing of Iopamidol raw materials [38] Group 10 - Zhejiang Liming's shareholder plans to reduce their stake by up to 2.93% [39] - Zhejiang Liming's actual controller has committed not to reduce their holdings within a year [40] - SAIC Motor reported a total vehicle sales of 2.0526 million units in the first half of 2025, a year-on-year increase of 12.35% [41] Group 11 - Xinhongcheng expects a net profit increase of 50%-70% for the first half of 2025 [42] - Xianhe Co. plans to invest 11 billion yuan in a bamboo pulp paper integrated project [42] - Great Wall Motors reported a total vehicle sales of 569,800 units in the first half of 2025, a year-on-year increase of 1.81% [43] Group 12 - Dongfeng Co. received a government subsidy of 10 million yuan [44] - Zhongke Environmental Protection has acquired two water environmental companies in Guangxi for a total of 353 million yuan [45] - Anji Food's H-share public offering is priced at 60 Hong Kong dollars per share [46]

证券代码：603990 证券简称：麦迪科技 公告编号：2025-046 苏州麦迪斯顿医疗科技股份有限公司 2025 年半年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次业绩预告为公司初步测算数据，未经审计。 二、 上年同期经营业绩和财务状况 2024年半年度公司业绩情况如下： 利润总额：-7,128.76万元 本期业绩预告适用情形:预计净利润实现扭亏为盈。 苏州麦迪斯顿医疗科技股份有限公司（以下简称"麦迪科技"或"公司"） 预计 2025 年半年度归属于母公司所有者的净利润为 2,500 万元至 2,700 万元，预计 2025 年半年度归属于母公司所有者的扣除非经常性损益的净 利润为 400 万元至 600 万元。 重要内容提示： 一、 本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年6月30日。 （二）业绩预告情况 经财务部门初步测算，预计公司2025年半年度实现归属于母公司所有者的净 利润为2,500万元至2,700万元，上年同期为-7,633.52万元，将实现扭亏为盈。 预计202 ...

麦迪科技：预计2025年上半年净利润2500万元-2700万元，同比扭亏为盈 金十数据7月2日讯，麦迪科技公告，预计2025年半年度归属于母公司所有者的净利润为2500万元至2700 万元，上年同期为-7633.52万元，将实现扭亏为盈。预计2025年半年度归属于母公司所有者的扣除非经 常性损益的净利润为400万元至600万元。 ...

北京市中伦（上海）律师事务所 关于苏州麦迪斯顿医疗科技股份有限公司 法律意见书 二〇二五年六月 法律意见书 北京市中伦（上海）律师事务所 关于苏州麦迪斯顿医疗科技股份有限公司 法律意见书 致：苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"） 北京市中伦（上海）律师事务所（以下简称"本所"）接受公司的委托，指 派律师出席并见证公司2025年第一次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）、《律师事务所从事证券法律业务管理办法》 （以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业 规则（试行）》（以下简称"《证券法律业务执业规则》"）等相关法律、行政 法规、规章、规范性文件及《苏州麦迪斯顿医疗科技股份有限公司章程》（以下 简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、 出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 资格、会议表决程序 ...

证券代码：603990 证券简称：麦迪科技 公告编号：2025-045 苏州麦迪斯顿医疗科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 6 月 30 日 (二)股东大会召开的地点：江苏省苏州市工业园区归家巷 222 号麦迪科技会议室 (五)公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 (一)非累积投票议案 1、 议案名称：关于公司 2024 年度未弥补亏损达到实收股本总额三分之一的议 案 审议结果：通过 表决情况：该项议案获得有效表决权股份总数的 1/2 以上通过。 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 359 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 72,105,470 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 ...

北京市中伦（上海）律师事务所 关于苏州麦迪斯顿医疗科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 二〇二五年六月 法律意见书 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）、《律师事务所从事证券法律业务管理办法》 （以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业 规则（试行）》（以下简称"《证券法律业务执业规则》"）等相关法律、行政 法规、规章、规范性文件及《苏州麦迪斯顿医疗科技股份有限公司章程》（以下 简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、 出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅就本次会议的召集与召开程序、召集人和出席现场会议人员 资格、会议表决程序及表决结果的合法性发表意见，不对本次会议所审议的议案 - 1 - 法律意见书 北京市中伦（上海）律师事务所 关于苏州麦迪斯顿医疗科技股份有限公司 2025 年第一次临时股东大会的 ...

Group 1 - The core viewpoint of the article is the strategic partnership between Shanghai Robotics Industry Technology Research Institute and Midea Technology (603990) to enhance the application of intelligent robots in healthcare, rehabilitation, and elderly care sectors [1] - The collaboration will focus on the joint development of embodied intelligent datasets, standardization construction, and scenario-based applications in the medical and wellness fields [1] - The partnership aims to promote the technological implementation and industrial ecosystem construction of intelligent robots in various healthcare-related scenarios [1]

Group 1 - The core viewpoint of the article highlights that Shangya Investment has conducted research on Medtronic Technology, which has been deeply engaged in medical information technology for twenty years and has developed integrated solutions covering over 2,400 medical institutions nationwide [1] - Medtronic Technology is in a phase of scale expansion and structural upgrading, indicating long-term growth potential. Traditional business growth points include smart surgery and emergency rescue, with competitive enhancement measures such as the introduction of large model technology and improved system collaboration capabilities [1] - The company is actively expanding into AI smart healthcare, low-altitude emergency rescue, and health care robotics, ensuring sufficient funding by changing the use of raised funds [1] Group 2 - The smart health care platform developed by Medtronic Technology addresses various needs of the elderly, including emotional support, medical care, health care, and safety monitoring, positioning the company as a comprehensive solution provider for smart health care [1] - The business model of Medtronic Technology is based on the delivery of integrated solutions combining software and hardware, leveraging high-quality medical data resources and complex scenario solution design capabilities in the humanoid robot sector [1] - The low-altitude emergency rescue business has launched an intelligent ED drone rescue solution, with plans for pilot deployment in Suzhou [1]

Core Viewpoint - The company, Madi Technology, is experiencing growth in its core business of medical information technology, focusing on expanding its scale and upgrading its structure, with significant long-term growth potential in the healthcare IT sector [1][3]. Group 1: Company Performance - As of June 27, 2025, Madi Technology's stock closed at 16.1 yuan, a 5.92% increase from the previous week, with a market capitalization of 4.931 billion yuan [1]. - The company’s core products, DoCare and DoRicon, are utilized in over 2,400 medical institutions across China, including nearly 1,200 tertiary hospitals [1]. Group 2: Business Development - Madi Technology is focusing on the development of a "software platform + smart hardware + algorithm engine" product system, targeting areas such as smart surgery and emergency rescue [1][2]. - The company has established an innovation department to focus on new business development, reallocating 43.5479 million yuan of previously raised funds for the "Innovation Product R&D Center Project" [2]. Group 3: Industry Trends - The healthcare IT spending in China is projected to reach 84.57 billion yuan by 2025, indicating a high growth phase for the industry [1]. - The company is positioning itself as a supplier of comprehensive smart healthcare solutions and is actively participating in pilot projects and the construction of smart healthcare platforms [4]. Group 4: Strategic Initiatives - Madi Technology is committed to building a data asset operation platform, exploring a closed-loop path from data collection to data assetization [3]. - The company is enhancing its clinical information systems and emergency rescue capabilities by integrating AI technologies to support decision-making and data management [3][4]. Group 5: Financial Management - The company has completed the implementation of several fundraising projects and has established new agreements for the management of raised funds to protect investor rights [5].